Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca CEO Says Post-Crestor Future On Track As Pipeline Builds

Executive Summary

AstraZeneca's first-half results presentation highlighted its growing early pipeline, notably in oncology, but also the increasing pain of generic erosion on its Crestor sales – underlining again the importance new drugs will play in the group's turnaround strategy.

Advertisement

Related Content

AstraZeneca’s Business Development Head Grady Outlines Strategy Mix
Crestor Generics To Launch After 12-Day Delay
UK Pharma Chiefs To Helm Brexit Steering Committee
AstraZeneca's 'Clear-Out' Strategy Sees Gout Drug Go To Grunenthal
Generic Crestor Marks The End Of An Era, Should Quickly Outperform PCSK9s
AstraZeneca BD Head Says More Out-Licensing, Divestment Expected In 2016
AstraZeneca Faces 'Key Pressures' But $45bn Sales Target 'Still Achievable'
AstraZeneca rebuffs Pfizer approach, report claims

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097009

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel